Xueyong Li, Yu Cheng, Bingqing Zhang, Bo Chen, Yiying Chen, Yingbing Huang, Hailing Lin, Lili Zhou, Hui Zhang, Maobai Liu, Wancai Que, Hongqiang Qiu
Polymyxin B (PMB) is considered a last-line treatment for multidrug-resistant (MDR) gram-negative bacterial infections. Model-informed precision dosing with population pharmacokinetics (PopPK) models could help to individualize PMB dosing regimens and improve therapy. However, the external prediction ability of the established PopPK models has not been fully elaborated. This study aimed to systemically evaluate eleven PMB PopPK models from ten published literature based on a new independent population, which was divided into four different populations, patients with liver dysfunction, kidney dysfunction, liver and kidney dysfunction, and normal liver and kidney function...
April 16, 2024: Journal of Pharmacokinetics and Pharmacodynamics